```html

Hepatitis D (Delta Hepatitis) – A Comprehensive Medical Guide

Overview

Hepatitis D, also called *delta hepatitis*, is a liver infection caused by the Hepatitis D virus (HDV). HDV is a defective, single‑stranded RNA virus that cannot replicate on its own; it requires the envelope proteins of Hepatitis B virus (HBV) to infect liver cells. Consequently, HDV infection occurs only in people who are already infected with HBV (co‑infection) or in those who acquire HDV after an established HBV infection (super‑infection).

**Who it affects** – HDV is found worldwide but is most common in regions where HBV is endemic, such as the Mediterranean basin, sub‑Saharan Africa, the Middle East, Central and South America, and parts of Asia. An estimated 15–20 million people are co‑infected with HDV and HBV globally, representing roughly 5 % of all chronic hepatitis B cases. In the United States, prevalence is low (<0.1 % of the population) but higher among people who inject drugs, men who have sex with men, and immigrants from high‑prevalence areas.

HDV infection accelerates liver damage; chronic HDV can lead to cirrhosis, liver failure, or hepatocellular carcinoma (HCC) faster than HBV alone.

Symptoms

Symptoms of hepatitis D can be subtle or overlap with other hepatitis infections. They may appear 2–12 weeks after exposure in acute infection or develop slowly in chronic disease.

Acute Hepatitis D

• Fever – low‑grade to high fever.
• Fatigue – profound tiredness, sometimes with malaise.
• Jaundice – yellowing of the skin and eyes due to elevated bilirubin.
• Dark urine – urine appears amber or brown.
• Pale stools – reduced bile pigment.
• Right‑upper‑quadrant abdominal pain – liver tenderness.
• Nausea/vomiting – may accompany loss of appetite.
• Joint or muscle aches – similar to flu‑like syndrome.

Chronic Hepatitis D

• Often asymptomatic for many years.
• Persistent fatigue and low‑grade abdominal discomfort.
• Progressive jaundice.
• Enlarged liver (hepatomegaly) or spleen (splenomegaly) on exam.
• Signs of cirrhosis: spider angiomas, palmar erythema, ascites, peripheral edema.
• Unexplained weight loss.
• Symptoms of liver cancer (HCC) in advanced disease: abdominal mass, weight loss, right‑shoulder pain.

Causes and Risk Factors

How HDV Causes Disease

HDV enters hepatocytes by binding to the same receptor used by HBV (the sodium taurocholate cotransporting polypeptide, NTCP). After entry, HDV uses the HBV surface antigen (HBsAg) to form its own viral envelope. Without HBV, HDV cannot produce infectious particles, making HBV infection a prerequisite.

Risk Factors

• Living with chronic HBV – the primary prerequisite.
• Injection drug use – sharing needles provides a direct route for both HBV and HDV.
• Unprotected sexual contact – especially with HBV‑positive partners.
• Mother‑to‑child transmission – in endemic areas, HBV‑positive mothers can transmit both viruses to newborns.
• Healthcare exposure – needlestick injuries or poorly sterilized equipment.
• Travel or residence in high‑prevalence regions – Mediterranean, parts of Africa, Asia, and South America.
• Hemodialysis – increased exposure to blood products.

Diagnosis

Because HDV requires HBV, a diagnostic work‑up always includes evaluation for both viruses.

Screening Tests

• HBsAg test – confirms ongoing HBV infection.
• Anti‑HDV antibodies (IgM and IgG) – detect exposure. IgM suggests recent infection; IgG indicates past or chronic infection.

Confirmatory Laboratory Tests

• HDV RNA PCR – quantitative test to measure viral load; essential for assessing disease activity and treatment response.
• Liver function tests (ALT, AST, bilirubin, ALP, GGT) – gauge liver inflammation.
• HBV DNA level – guides HBV management; high HBV DNA can worsen HDV disease.

Imaging & Staging

• Ultrasound – first‑line to evaluate liver texture, detect cirrhosis or focal lesions.
• Transient elastography (FibroScan) – non‑invasive measurement of liver stiffness.
• CT or MRI – used when cancer is suspected or for detailed mapping before a liver transplant.

When to Test

Guidelines from the CDC and the WHO recommend HDV testing in anyone who is HBsAg‑positive and:

1. Lives in or originates from a high‑prevalence region.
2. Has a history of injection drug use.
3. Engages in high‑risk sexual behavior.
4. Shows unexplained liver enzyme elevation.

Treatment Options

Therapeutic strategies target both HDV replication and the underlying HBV infection.

Antiviral Medications

• Bulevirtide (Hepcludex®) – the first FDA‑approved drug specifically for chronic HDV (approved 2022). It blocks NTCP, preventing HDV entry into hepatocytes. Typical regimen: 2 mg subcutaneous injection daily. Clinical trials showed a 70 % sustained virologic response at 48 weeks.
• Pegylated interferon‑alpha (PEG‑IFN‑α) – historically the mainstay. Given weekly for 48–96 weeks; response rates ~30‑40 % but associated with flu‑like side effects, depression, and cytopenias.
• Tenofovir or Entecavir – potent nucleos(t)ide analogues for HBV. They do not directly suppress HDV but controlling HBV reduces the supply of HBsAg needed for HDV assembly, enhancing overall outcomes.

Investigational Therapies (clinical trials)

• Lonafarnib – a farnesyltransferase inhibitor that interferes with HDV particle maturation; being studied in combination with ritonavir.
• REP 2139/2155 (RNAi therapeutics) – target HBsAg production, indirectly limiting HDV replication.

Procedural Interventions

• Liver transplantation – reserved for end‑stage liver disease or fulminant failure. Post‑transplant antiviral prophylaxis (HBV immunoglobulin + nucleos(t)ide analogue) is essential to prevent reinfection.

Lifestyle & Supportive Measures

• Complete abstinence from alcohol – alcohol accelerates liver injury.
• Balanced diet rich in fruits, vegetables, lean protein, and low in saturated fats.
• Vaccination against hepatitis A and completion of hepatitis B vaccination (if not already immune) to prevent additional hepatic insults.
• Regular follow‑up every 3–6 months with liver function tests and imaging.

Living with Hepatitis D

Daily Management Tips

• Medication adherence – set alarms or use pillboxes for daily antivirals and weekly interferon injections.
• Monitor symptoms – keep a diary of fatigue, abdominal pain, or changes in skin color; report new issues promptly.
• Healthy weight – obesity worsens liver fibrosis; aim for a BMI < 25 kg/m².
• Physical activity – moderate exercise (e.g., brisk walking 150 min/week) improves liver enzymes and overall wellbeing.
• Avoid hepatotoxic substances – over‑the‑counter pain relievers like acetaminophen should be limited to ≤2 g/day; avoid illicit drugs and unregulated herbal supplements.
• Regular screening for liver cancer – ultrasound ± α‑fetoprotein every 6 months per AASLD guidelines.

Psychosocial Support

Living with a chronic viral hepatitis can be stressful. Consider:

• Joining support groups (online or local) for hepatitis B/D patients.
• Speaking with a mental‑health professional if you experience anxiety, depression, or stigma.
• Education for family members about transmission risk and vaccination.

Prevention

• HBV vaccination – the most effective way to prevent HDV, because without HBV there is no host for HDV. The recombinant hepatitis B vaccine series (3 doses) provides >95 % protection.
• Safe injection practices – never share needles or syringes; use sterile equipment for tattoos, piercings, and medical procedures.
• Barrier protection – consistent condom use reduces sexual transmission of HBV/HDV.
• Screening of blood products – all donated blood is screened for HBV; however, in some low‑resource settings, ensure that transfusions are from vetted sources.
• Education of high‑risk groups – targeted outreach to people who inject drugs, men who have sex with men, and migrants from endemic regions.

Complications

If left untreated or inadequately managed, hepatitis D can progress rapidly.

• Cirrhosis – scarring of the liver; occurs in 70–80 % of chronic HDV patients within 10–15 years.
• Decompensated liver disease – ascites, variceal bleeding, hepatic encephalopathy.
• Hepatocellular carcinoma (HCC) – risk is 2–3 times higher than in HBV monoinfection.
• Liver transplantation – required in end‑stage disease; post‑transplant recurrence is possible without adequate HBV suppression.
• Increased mortality – studies cite a 5‑year survival of ~70 % for chronic HDV versus 90 % for HBV alone.

When to Seek Emergency Care

References

1. Mayo Clinic. “Hepatitis D (Delta Hepatitis).” https://www.mayoclinic.org/diseases-conditions/hepatitis-d/symptoms-causes/syc-20354959
2. World Health Organization. “Hepatitis D.” Fact sheet, 2022. https://www.who.int/news-room/fact-sheets/detail/hepatitis-d
3. Centers for Disease Control and Prevention. “Hepatitis D (Delta) Virus.” 2023. https://www.cdc.gov/hepatitis/hdv/index.htm
4. European Association for the Study of the Liver (EASL). “EASL Clinical Practice Guidelines: Management of hepatitis D virus infection.” *Journal of Hepatology*, 2022.
5. American Association for the Study of Liver Diseases (AASLD). “Guidelines for the Treatment of Hepatitis B and D.” 2023.
6. Fornasiere, J. et al. “Bulevirtide for chronic hepatitis D infection.” *New England Journal of Medicine*, 2022; 387: 874‑884.
7. Pradeau, A. et al. “Long‑term outcomes of hepatitis D infection.” *Lancet Gastroenterology & Hepatology*, 2021; 6: 493‑504.

```